Should You Dump AstraZeneca plc And Buy BTG plc & Silence Therapeutics plc?

Do BTG plc (LON:BTG) and Silence Therapeutics plc (LON:SLN) have better prospects than AstraZeneca plc (LON:AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sales and earnings at AstraZeneca (LSE: AZN) have been disappointing in recent years. Could it be time to give the FTSE 100 pharma giant the elbow and look instead to FTSE 250 growth stock BTG (LSE: BTG) or AIM-listed biotech Silence Therapeutics (LSE: SLN)?

Astra versus BTG

AstraZeneca has seen annual earnings declines that have totted up to the extent that 2015 earnings came in some 40% lower than in 2011. And earnings are set for further falls in both the current year and 2017, according to City consensus forecasts.

In contrast, BTG’s earnings have been on the rise, and the consensus forecast yesterday was for an 18% increase for the company’s financial year ending 31 March. That may be revised upwards somewhat, after the company said in a pre-close trading update today that revenue for the year is now expected to be at the upper end of its guidance range, albeit boosted by currency tailwinds.

With BTG reinvesting cash generated from its specialty pharmaceuticals and licensing businesses into its interventional medicine portfolio, analysts expect earnings to accelerate higher in the next two years, with growth of around 20% rocketing to 40%. If the company delivers, a current price-to-earnings (P/E) ratio of well above 30 would fall to around 20.

BTG appears to have a clear routemap for producing strong long-term earnings growth, and the shares could prove to be a good buy at their current 625p level.

However, I believe Astra also offers excellent value right now. The shares are trading at below £40, and the P/E on what is expected to be the bottom of the company’s earnings declines next year is an attractive 14, with a 5% dividend yield to boot.

Despite going through a difficult period, Astra’s medium-to-long-term future is looking bright, which is perhaps recognised by the £55-a-share offer US giant Pfizer made for the company a couple of years ago.

Silence Therapeutics

Silence Therapeutics is a very different proposition to Astra and BTG in that earnings are currently negative. In fact, the company doesn’t even generate any revenue — and the situation isn’t expected to change for a few years yet.

This small biotech firm — it has a market cap of £86m at a current share price of 123p — describes itself as “a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases “.

I always find it irritating when companies use unexplained specialist acronyms, initialisms and other abbreviations in their communications to investors and potential investors. I had to look up RNA, which would seem to be ribonucleic acid, which is apparently important in the coding, decoding, regulation, and expression of genes.

Silence has been burning less than £10m a year cash on developing its pipeline, and with net cash of £52m reported in its annual results today, the company is clearly well-funded. However, putting an appropriate valuation on the business at this stage is not easy. As such, I would be more comfortable investing in Astra and BTG.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »